

Special Issue

Exploring Potential Therapeutic Compounds with Anti-Inflammatory Activity

Message from the Guest Editor

The Special Issue titled “Exploring Potential Therapeutic Compounds with Anti-Inflammatory Activity” aims to identify the efficacy of potential therapeutic compounds against a variety of inflammatory diseases. The scope of this Special Issue includes exploring numerous strategies in preclinical and clinical trials to study the usefulness of several compounds such as epigallocatechin 3-gallate, Genistein, mushroom polysaccharides, metalloporphyrins, etc. We invite novel research involving the therapeutic use of these particular aforementioned compounds against various inflammatory diseases. Publishing this Special Issue provides a platform for the researchers to share their novel work and foster interdisciplinary collaboration which will improve the clinical applications of these therapeutic compounds. We invite contributions to this Special Issue in the form of original research articles and reviews, and I hope that this Special Issue will be of great interest to a wide range of readers of this journal.

Guest Editor

Dr. Shomaila Mehmood

Wayne State University, Institute of Environmental Health Sciences,
Detroit, Michigan, United States

Deadline for manuscript submissions

closed (31 January 2026)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/227390

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).